On Thursday, TCF Financial Corporation (NYSE:TCB)’s shares declined -2.87% to $15.23.
The Board of Directors of TCF Financial Corporation (TCF) (TCB) recently declared that Craig R. Dahl, vice chairman and president, will succeed William A. Cooper as chief executive officer effective January 1, 2016. Cooper will remain chairman through 2017.
Dahl joined TCF in 1999 as president and chief executive officer of TCF Equipment Finance, Inc. and later was named president and chief executive officer of Winthrop Resources Corporation. He began serving as vice chairman of TCF in 2012 and was promoted to president in 2015. Dahl presently oversees TCF’s six lending businesses, Retail Banking and information technology. Preceding to joining TCF, he held a number of leadership positions with a major financial services company for 22 years. Dahl holds a bachelor’s degree in political economics from Princeton University and is a native of International Falls, Minnesota.
TCF Financial Corporation operates as the bank holding company for TCF National Bank that provides various retail and commercial banking products and services. The companys Lending segment offers retail lending services, counting consumer loans for personal, family, and household purposes, such as home purchases, debt consolidation, and financing of home improvements.
Cerner Corporation (NASDAQ:CERN)’s shares gained 1.78% to $64.52.
Cerner Corporation (CERN) recently declared that its board of directors approved a stock repurchase program on Sept. 4, 2015, at its regularly planned Board meeting, authorizing the repurchase of up to $245 million of its common stock. The company plans to repurchase shares from time to time in the open market, by block purchase, or possibly through other transactions managed by broker-dealers. No time limit was set for completion of the program.
Based on the Sept. 4, 2015 closing price, about 4.1 million shares, or 1.2 percent of the company’s outstanding shares, could be repurchased. The repurchase is intended to offset a portion of the dilution created by future equity grants and will be funded from working capital. The previous stock repurchase program approved by Cerner’s board of directors in December 2013, which was amended in May 2014, has been accomplished.
Cerner Corporation designs, develops, markets, installs, hosts, and supports healthcare information technology, healthcare devices, hardware, and content solutions for healthcare organizations and consumers in the United States and internationally. The company offers Cerner Millennium architecture, which comprises clinical, financial, and administration information systems that allow providers to access an individual’s electronic health record at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front and back-office professionals, and consumers.
At the end of Thursday’s trade, Anthera Pharmaceuticals Inc (NASDAQ:ANTH)‘s shares surged 18.80% to $9.48.
Anthera Pharmaceuticals, Inc. (ANTH) declared receipt of a termination notice from its development partner in Japan, Zenyaku, terminating the December 2014 Partnership and License Agreement effective January 7, 2016. The termination was “at will” and alleged no breach of the License Agreement by Anthera. At the time of the notification, no patients had been enrolled in any blisibimod clinical studies in the Zenyaku territory and Zenyaku had not purchased any blisibimod product from Anthera.
As formerly revealed, Anthera reached a partnership and license agreement with Zenyaku in December 2014. The License Agreement required Zenyaku, subject to mutually agreed timelines, to develop and commercialize blisibimod in Japan. Preceding to the notification of termination Zenyaku purchased $9.0 million of Anthera common stock at a thirty-percent premium to a trailing market price.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others.
Lincoln National Corporation (NYSE:LNC), ended its Thursday’s trading session with -2.78% loss, and closed at $49.33.
Lincoln Financial Group (LNC) declared that it will report its third quarter earnings after market close on Wednesday, October 28, 2015. A conference call is planned for Thursday, October 29, 2015, at 10:00 a.m. Eastern Time, to talk about third quarter earnings and related matters for the company and its business segments.
Lincoln National Corporation, through its auxiliaries, engages in multiple insurance and retirement businesses in the United States. It operates through Annuities, Retirement Plan Services, Life Insurance, and Group Protection segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
